Cluster composition

Functions

CategoryNameIntersectionWithQueryPValueGenesInTermGenesInQueryGenesInTermInQueryID
GeneOntologyBiologicalProcessnegative regulation of vascular associated smooth muscle cell differentiation

NFATC1 NFATC3

3.32e-0513142GO:1905064
GeneOntologyBiologicalProcessnegative regulation of smooth muscle cell differentiation

NFATC1 NFATC3

1.17e-0424142GO:0051151
GeneOntologyBiologicalProcessregulation of vascular associated smooth muscle cell differentiation

NFATC1 NFATC3

1.27e-0425142GO:1905063
GeneOntologyBiologicalProcessnegative regulation of telomere maintenance via telomere lengthening

SLX4 TNKS2

2.23e-0433142GO:1904357
MousePhenoabnormal placement of pupils

SNIP1 SLX4

6.11e-0514122MP:0006241
DomainNFAT

NFATC1 NFATC3

5.21e-065142IPR008366
DomainRHD_DNA_bind_dom

NFATC1 NFATC3

2.34e-0510142IPR011539
DomainREL_2

NFATC1 NFATC3

2.34e-0510142PS50254
DomainRHD_dimer

NFATC1 NFATC3

2.34e-0510142IPR032397
DomainRHD_dimer

NFATC1 NFATC3

2.34e-0510142PF16179
DomainRHD_DNA_bind

NFATC1 NFATC3

2.34e-0510142PF00554
Domain-

NFATC1 NFATC3

2.34e-05101422.60.40.340
DomainNFkB/Dor

NFATC1 NFATC3

2.34e-0510142IPR000451
DomainREL_1

NFATC1 NFATC3

2.34e-0510142PS01204
DomainIPT

NFATC1 NFATC3

1.81e-0427142SM00429
DomainTIG

NFATC1 NFATC3

2.40e-0431142PF01833
DomainIPT

NFATC1 NFATC3

2.55e-0432142IPR002909
Domainp53-like_TF_DNA-bd

NFATC1 NFATC3

7.03e-0453142IPR008967
DomainIg_E-set

NFATC1 NFATC3

2.68e-03104142IPR014756
DomainPH

IRS2 IQSEC2

1.79e-02278142SM00233
DomainPH_DOMAIN

IRS2 IQSEC2

1.80e-02279142PS50003
DomainPH_domain

IRS2 IQSEC2

1.81e-02280142IPR001849
PathwayREACTOME_CALCINEURIN_ACTIVATES_NFAT

NFATC1 NFATC3

1.63e-059102M27106
PathwayREACTOME_CALCINEURIN_ACTIVATES_NFAT

NFATC1 NFATC3

2.48e-0511102MM14810
PathwayREACTOME_CLEC7A_DECTIN_1_INDUCES_NFAT_ACTIVATION

NFATC1 NFATC3

2.48e-0511102M27466
PathwayKEGG_MEDICUS_REFERENCE_CA2_CAM_CN_SIGNALING_PATHWAY

NFATC1 NFATC3

2.98e-0512102M47956
PathwayKEGG_MEDICUS_REFERENCE_EGF_EGFR_PLCG_CALCINEURIN_SIGNALING_PATHWAY

NFATC1 NFATC3

5.41e-0516102M47449
PathwayKEGG_MEDICUS_PATHOGEN_HIV_GP120_TO_CXCR4_GNAQ_PLCB_G_CALCINEURIN

NFATC1 NFATC3

6.12e-0517102M47560
PathwayBIOCARTA_CALCINEURIN_PATHWAY

NFATC1 NFATC3

6.89e-0518102M3430
PathwayBIOCARTA_CALCINEURIN_PATHWAY

NFATC1 NFATC3

6.89e-0518102MM1385
PathwayKEGG_MEDICUS_REFERENCE_BCR_PLCG_CALCINEURIN_SIGNALING_PATHWAY

NFATC1 NFATC3

6.89e-0518102M47580
PathwayKEGG_MEDICUS_PATHOGEN_HCMV_US28_TO_GNAQ_PLCB_G_CALCINEURIN_SIGNALING_PATHWAY

NFATC1 NFATC3

7.70e-0519102M47543
PathwayKEGG_AXON_GUIDANCE

NFATC1 NFATC3 SRGAP1

8.57e-05129103M5539
PathwayKEGG_MEDICUS_REFERENCE_CXCR4_GNAQ_PLCB_G_CALCINEURIN_SIGNALING_PATHWAY

NFATC1 NFATC3

9.44e-0521102M47542
PathwayWP_CANCER_IMMUNOTHERAPY_BY_PD1_BLOCKADE

NFATC1 NFATC3

1.14e-0423102M39843
PathwayPID_TCR_CALCIUM_PATHWAY

NFATC1 NFATC3

1.70e-0428102M235
PathwayBIOCARTA_GPCR_PATHWAY

NFATC1 NFATC3

1.82e-0429102MM1495
PathwayBIOCARTA_GPCR_PATHWAY

NFATC1 NFATC3

1.95e-0430102M9664
PathwayBIOCARTA_BCR_PATHWAY

NFATC1 NFATC3

2.22e-0432102MM1355
PathwayWP_INITIATION_OF_TRANSCRIPTION_AND_TRANSLATION_ELONGATION_AT_THE_HIV1_LTR

NFATC1 NFATC3

2.22e-0432102M39521
PathwayBIOCARTA_BCR_PATHWAY

NFATC1 NFATC3

2.36e-0433102M9494
PathwayBIOCARTA_FMLP_PATHWAY

NFATC1 NFATC3

2.51e-0434102M10287
PathwayBIOCARTA_FMLP_PATHWAY

NFATC1 NFATC3

2.51e-0434102MM1399
PathwayPID_FRA_PATHWAY

NFATC1 NFATC3

2.98e-0437102M65
PathwayBIOCARTA_FCER1_PATHWAY

NFATC1 NFATC3

3.31e-0439102M1908
PathwayBIOCARTA_FCER1_PATHWAY

NFATC1 NFATC3

3.31e-0439102MM1397
PathwayBIOCARTA_TCR_PATHWAY

NFATC1 NFATC3

3.84e-0442102MM1504
PathwayBIOCARTA_TCR_PATHWAY

NFATC1 NFATC3

4.22e-0444102M19784
PathwayPID_NFAT_TFPATHWAY

NFATC1 NFATC3

4.41e-0445102M60
PathwayWP_HEART_DEVELOPMENT

NFATC1 NFATC3

4.61e-0446102MM15884
PathwayWP_HEART_DEVELOPMENT

NFATC1 NFATC3

4.81e-0447102M39610
PathwayBIOCARTA_NFAT_PATHWAY

NFATC1 NFATC3

5.23e-0449102MM1442
PathwayBIOCARTA_NFAT_PATHWAY

NFATC1 NFATC3

5.67e-0451102M2288
PathwayPID_NFAT_3PATHWAY

NFATC1 NFATC3

6.12e-0453102M113
PathwayREACTOME_FCERI_MEDIATED_CA_2_MOBILIZATION

NFATC1 NFATC3

7.33e-0458102MM14914
PathwayPID_CD8_TCR_DOWNSTREAM_PATHWAY

NFATC1 NFATC3

9.20e-0465102M272
PathwayPID_AP1_PATHWAY

NFATC1 NFATC3

1.07e-0370102M167
PathwayKEGG_B_CELL_RECEPTOR_SIGNALING_PATHWAY

NFATC1 NFATC3

1.22e-0375102M5436
PathwayKEGG_VEGF_SIGNALING_PATHWAY

NFATC1 NFATC3

1.26e-0376102M1749
PathwayREACTOME_DOWNSTREAM_SIGNALING_EVENTS_OF_B_CELL_RECEPTOR_BCR

NFATC1 NFATC3

1.29e-0377102MM14513
PathwayREACTOME_DOWNSTREAM_SIGNALING_EVENTS_OF_B_CELL_RECEPTOR_BCR

NFATC1 NFATC3

1.42e-0381102M595
PathwayREACTOME_FCERI_MEDIATED_CA_2_MOBILIZATION

NFATC1 NFATC3

1.60e-0386102M27206
PathwayREACTOME_CLEC7A_DECTIN_1_SIGNALING

NFATC1 NFATC3

1.87e-0393102MM15204
PathwayREACTOME_CLEC7A_DECTIN_1_SIGNALING

NFATC1 NFATC3

2.16e-03100102M27467
PathwayKEGG_T_CELL_RECEPTOR_SIGNALING_PATHWAY

NFATC1 NFATC3

2.51e-03108102M9904
PathwayREACTOME_C_TYPE_LECTIN_RECEPTORS_CLRS

NFATC1 NFATC3

2.70e-03112102MM15214
PathwayWP_WNT_SIGNALING_WP428

NFATC1 NFATC3

2.75e-03113102M39669
PathwayREACTOME_SIGNALING_BY_THE_B_CELL_RECEPTOR_BCR

NFATC1 NFATC3

3.67e-03131102MM15717
PathwayKEGG_NATURAL_KILLER_CELL_MEDIATED_CYTOTOXICITY

NFATC1 NFATC3

4.01e-03137102M5669
PathwayREACTOME_C_TYPE_LECTIN_RECEPTORS_CLRS

NFATC1 NFATC3

4.18e-03140102M27484
PathwayREACTOME_FC_EPSILON_RECEPTOR_FCERI_SIGNALING

NFATC1 NFATC3

4.79e-03150102MM14889
PathwayKEGG_WNT_SIGNALING_PATHWAY

NFATC1 NFATC3

4.85e-03151102M19428
PathwayWP_HEPATITIS_B_INFECTION

NFATC1 NFATC3

4.85e-03151102M39801
PathwayREACTOME_SIGNALING_BY_THE_B_CELL_RECEPTOR_BCR

NFATC1 NFATC3

5.83e-03166102M608
PathwayREACTOME_FC_EPSILON_RECEPTOR_FCERI_SIGNALING

NFATC1 NFATC3

7.27e-03186102M27175
PathwayREACTOME_SIGNALING_BY_WNT

NFATC1 TNKS2

1.18e-02239102MM14756
PathwayWP_MAPK_SIGNALING

NFATC1 NFATC3

1.24e-02246102M39597
PathwayREACTOME_INTRACELLULAR_SIGNALING_BY_SECOND_MESSENGERS

IRS2 TNKS2

1.30e-02252102MM15585
PathwayREACTOME_INTRACELLULAR_SIGNALING_BY_SECOND_MESSENGERS

IRS2 TNKS2

1.97e-02313102M27867
Pubmed

Coupling bimolecular PARylation biosensors with genetic screens to identify PARylation targets.

CTIF TNKS2

1.50e-07214229789535
Pubmed

High extracellular calcium-induced NFATc3 regulates the expression of receptor activator of NF-κB ligand in osteoblasts.

NFATC1 NFATC3

1.50e-07214221514407
Pubmed

Molecular cloning and functional characterization of murine cDNA encoding transcription factor NFATc.

NFATC1 NFATC3

4.51e-0731429388475
Pubmed

NFATc3, a lymphoid-specific NFATc family member that is calcium-regulated and exhibits distinct DNA binding specificity.

NFATC1 NFATC3

4.51e-0731427650004
Pubmed

Specific and redundant roles for NFAT transcription factors in the expression of mast cell-derived cytokines.

NFATC1 NFATC3

4.51e-07314217082579
Pubmed

NFAT transcription factors are essential and redundant actors for leukemia initiating potential in T-cell acute lymphoblastic leukemia.

NFATC1 NFATC3

4.51e-07314234234374
Pubmed

The transcription factor NFAT4 is involved in the generation and survival of T cells.

NFATC1 NFATC3

4.51e-0731429768749
Pubmed

Dependence on nuclear factor of activated T-cells (NFAT) levels discriminates conventional T cells from Foxp3+ regulatory T cells.

NFATC1 NFATC3

9.02e-07414222991461
Pubmed

Alternative splicing and expression of human and mouse NFAT genes.

NFATC1 NFATC3

9.02e-07414218675896
Pubmed

Transcription factors of the NFAT family: regulation and function.

NFATC1 NFATC3

9.02e-0741429143705
Pubmed

Sequential involvement of NFAT and Egr transcription factors in FasL regulation.

NFATC1 NFATC3

9.02e-07414210755616
Pubmed

Nuclear factor of activated T cells is activated in the endothelium of retinal microvessels in diabetic mice.

NFATC1 NFATC3

9.02e-07414225918731
Pubmed

Normal B-1a cell development requires B cell-intrinsic NFATc1 activity.

NFATC1 NFATC3

9.02e-07414214595020
Pubmed

The transcription factor nuclear factor of activated T cells c3 modulates the function of macrophages in sepsis.

NFATC1 NFATC3

9.02e-07414224970700
Pubmed

HIV-1 gp120 induces NFAT nuclear translocation in resting CD4+ T-cells.

NFATC1 NFATC3

9.02e-07414216260021
Pubmed

Calcineurin regulates innate antifungal immunity in neutrophils.

NFATC1 NFATC3

9.02e-07414220421389
Pubmed

Defective T cell development and function in calcineurin A beta -deficient mice.

NFATC1 NFATC3

9.02e-07414212091710
Pubmed

NFAT isoforms play distinct roles in TNFα-induced retinal leukostasis.

NFATC1 NFATC3

9.02e-07414226527057
Pubmed

Down syndrome critical region-1 is a transcriptional target of nuclear factor of activated T cells-c1 within the endocardium during heart development.

NFATC1 NFATC3

1.50e-06514217693409
Pubmed

Selective role of NFATc3 in positive selection of thymocytes.

NFATC1 NFATC3

1.50e-06514217579027
Pubmed

Human immunodeficiency virus type-1 tat enhances interleukin-2 promoter activity through synergism with phorbol ester and calcium-mediated activation of the NF-AT cis-regulatory motif.

NFATC1 NFATC3

1.50e-0651427999066
Pubmed

Expression of human endogenous retrovirus type K (HML-2) is activated by the Tat protein of HIV-1.

NFATC1 NFATC3

1.50e-06514222593154
Pubmed

Calcineurin B1 is essential for positive but not negative selection during thymocyte development.

NFATC1 NFATC3

1.50e-06514215030770
Pubmed

Generic signals and specific outcomes: signaling through Ca2+, calcineurin, and NF-AT.

NFATC1 NFATC3

1.50e-06514210089876
Pubmed

NFAT: ubiquitous regulator of cell differentiation and adaptation.

NFATC1 NFATC3

1.50e-06514211877454
Pubmed

Cyclosporin A sensitivity of the HIV-1 long terminal repeat identifies distinct p56lck-dependent pathways activated by CD4 triggering.

NFATC1 NFATC3

2.25e-0661428814265
Pubmed

Calcineurin-dependent nuclear translocation of a murine transcription factor NFATx: molecular cloning and functional characterization.

NFATC1 NFATC3

2.25e-0661429017603
Pubmed

Human immunodeficiency virus type 1 Tat increases cooperation between AP-1 and NFAT transcription factors in T cells.

NFATC1 NFATC3

2.25e-06614216690925
Pubmed

Increased dosage of DYRK1A and DSCR1 delays neuronal differentiation in neocortical progenitor cells.

NFATC1 NFATC3

2.25e-06614224352425
Pubmed

Regulation of T cell activation by HIV-1 accessory proteins: Vpr acts via distinct mechanisms to cooperate with Nef in NFAT-directed gene expression and to promote transactivation by CREB.

NFATC1 NFATC3

2.25e-06614212788643
Pubmed

A strategy for probing the function of noncoding RNAs finds a repressor of NFAT.

NFATC1 NFATC3

2.25e-06614216141075
Pubmed

The lncRNA NRON modulates HIV-1 replication in a NFAT-dependent manner and is differentially regulated by early and late viral proteins.

NFATC1 NFATC3

2.25e-06614225728138
Pubmed

A field of myocardial-endocardial NFAT signaling underlies heart valve morphogenesis.

NFATC1 NFATC3

2.25e-06614215339668
Pubmed

NFAT dysregulation by increased dosage of DSCR1 and DYRK1A on chromosome 21.

NFATC1 NFATC3

3.16e-06714216554754
Pubmed

Extracellular HIV-Tat induces cyclooxygenase-2 in glial cells through activation of nuclear factor of activated T cells.

NFATC1 NFATC3

3.16e-06714218097055
Pubmed

Calcium/NFAT signalling promotes early nephrogenesis.

NFATC1 NFATC3

3.16e-06714221295565
Pubmed

Epithelial calcineurin controls microbiota-dependent intestinal tumor development.

NFATC1 NFATC3

3.16e-06714227043494
Pubmed

Scleraxis and NFATc regulate the expression of the pro-alpha1(I) collagen gene in tendon fibroblasts.

NFATC1 NFATC3

3.16e-06714217430895
Pubmed

MicroRNA-124 suppresses the transactivation of nuclear factor of activated T cells by targeting multiple genes and inhibits the proliferation of pulmonary artery smooth muscle cells.

NFATC1 NFATC3

4.21e-06814223853098
Pubmed

NFATc1 regulates lymphatic endothelial development.

NFATC1 NFATC3

4.21e-06814219233265
Pubmed

Targeted disruption of NFATc3, but not NFATc4, reveals an intrinsic defect in calcineurin-mediated cardiac hypertrophic growth.

NFATC1 NFATC3

4.21e-06814212370307
Pubmed

Interaction of HIV gp120 and anti-CD4 antibodies with the CD4 molecule on human CD4+ T cells inhibits the binding activity of NF-AT, NF-kappa B and AP-1, three nuclear factors regulating interleukin-2 gene enhancer activity.

NFATC1 NFATC3

4.21e-0681427957556
Pubmed

Microbiota-dependent activation of the myeloid calcineurin-NFAT pathway inhibits B7H3- and B7H4-dependent anti-tumor immunity in colorectal cancer.

NFATC1 NFATC3

5.41e-06914235364006
Pubmed

Spatial and temporal regulation of coronary vessel formation by calcineurin-NFAT signaling.

NFATC1 NFATC3

6.76e-061014219710169
Pubmed

A central chaperone-like role for 14-3-3 proteins in human cells.

MAST2 NFATC3 SRGAP1 IRS2 IQSEC2

1.53e-0586114536931259
Pubmed

Using genetic and clinical factors to predict tacrolimus dose in renal transplant recipients.

NFATC1 NFATC3

1.58e-051514221047202
Pubmed

Overexpression of TEAD-1 in transgenic mouse striated muscles produces a slower skeletal muscle contractile phenotype.

NFATC1 NFATC3

2.85e-052014218978355
Pubmed

A new role for the calcineurin/NFAT pathway in neonatal myosin heavy chain expression via the NFATc2/MyoD complex during mouse myogenesis.

NFATC1 NFATC3

3.46e-052214224301466
Pubmed

Comprehensive proteomic analysis of interphase and mitotic 14-3-3-binding proteins.

NFATC1 SRGAP1 IRS2

5.59e-0519014315161933
Pubmed

Signaling pathways triggered by HIV-1 Tat in human monocytes to induce TNF-alpha.

NFATC1 NFATC3

1.05e-043814212482669
Pubmed

Signals transduced by Ca(2+)/calcineurin and NFATc3/c4 pattern the developing vasculature.

NFATC1 NFATC3

1.28e-044214211439183
Pubmed

Dosage-dependent transcriptional regulation by the calcineurin/NFAT signaling in developing myocardium transition.

NFATC1 NFATC3

1.61e-044714217198697
Pubmed

New genetic associations detected in a host response study to hepatitis B vaccine.

NFATC1 NFATC3 SRGAP1 TNKS2

2.59e-0482414420237496
Pubmed

SR protein kinases promote splicing of nonconsensus introns.

MAST2 SNIP1 IRS2

3.71e-0436114326167880
Pubmed

A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells.

NFATC3 SNIP1

3.89e-047314222094256
CytobandEnsembl 112 genes in cytogenetic band chr1p34

MAST2 SNIP1

3.53e-03294142chr1p34
CytobandEnsembl 112 genes in cytogenetic band chr17q25

OTOP2 CANT1

3.85e-03307142chr17q25
GeneFamilyNuclear factors of activated T-cells

NFATC1 NFATC3

1.71e-06582665
CoexpressionSOBOLEV_T_CELL_PANDEMRIX_AGE_18_64YO_7DY_DN

NFATC1 NFATC3

5.53e-0521142M41206
CoexpressionSOBOLEV_T_CELL_PANDEMRIX_AGE_18_64YO_1DY_UP

NFATC1 NFATC3

6.66e-0523142M41207
CoexpressionDESCARTES_FETAL_STOMACH_LYMPHATIC_ENDOTHELIAL_CELLS

NFATC1 RTN4RL1

7.26e-0524142M40311
CoexpressionSCHERER_PBMC_APSV_WETVAX_AGE_18_32YO_50_TO_60DY_UP

SNIP1 IRS2 TNKS2

9.10e-05169143M40877
CoexpressionGSE36392_TYPE_2_MYELOID_VS_EOSINOPHIL_IL25_TREATED_LUNG_UP

MAST2 SRGAP1 IQSEC2

1.48e-04199143M5270
CoexpressionGSE43955_TH0_VS_TGFB_IL6_TH17_ACT_CD4_TCELL_1H_DN

NFATC1 CANT1 SNIP1

1.50e-04200143M9637
CoexpressionGSE19923_WT_VS_HEB_AND_E2A_KO_DP_THYMOCYTE_DN

NFATC1 SNIP1 IRS2

1.50e-04200143M7269
CoexpressionGSE35825_IFNA_VS_IFNG_STIM_MACROPHAGE_DN

NFATC3 RTN4RL1 TNKS2

1.50e-04200143M8656
CoexpressionGSE43863_DAY6_EFF_VS_DAY150_MEM_LY6C_INT_CXCR5POS_CD4_TCELL_UP

NFATC1 SLX4 IRS2

1.50e-04200143M9748
CoexpressionGSE2585_CTEC_VS_THYMIC_MACROPHAGE_UP

RTN4RL1 SRGAP1 IRS2

1.50e-04200143M6268
CoexpressionHARALAMBIEVA_PBMC_FLUARIX_AGE_50_74YO_CORR_WITH_28D_MEM_B_CELL_RESPONSE_AT_28DY_POSITIVE

SNIP1 SLX4 CTIF IRS2 IQSEC2

3.41e-041250145M41099
ToppCell10x5'v1-week_14-16-Myeloid_macrophage-stroma-osteoclast|week_14-16 / cell types per 3 fetal stages;per 3',per 5'

NFATC1 SRGAP1 IQSEC2

2.15e-05178143a28683690ab8a60eb18f3ef87ea85da4e95b22df
ToppCell10x3'2.3-week_14-16-Myeloid_macrophage-stroma-osteoclast|week_14-16 / cell types per 3 fetal stages;per 3',per 5'

NFATC1 SRGAP1 IQSEC2

2.41e-051851435ed49b6d8214c6119355a6d3ee4e25d40bcc0c53
ToppCell10x5'v1-week_12-13-Myeloid_macrophage-stroma-osteoclast|week_12-13 / cell types per 3 fetal stages;per 3',per 5'

NFATC1 SRGAP1 IQSEC2

2.45e-05186143c9dfcf7bba7e5ef97ad5d9b7084fba932c91ab68
ToppCell10x5'v1-week_17-19-Myeloid_macrophage-stroma-osteoclast|week_17-19 / cell types per 3 fetal stages;per 3',per 5'

NFATC1 SRGAP1 IQSEC2

2.53e-05188143762b52f21d2bc5409f86746a904c4358490be9c0
ToppCell10x5'v1-week_12-13-Myeloid_macrophage-stroma|week_12-13 / cell types per 3 fetal stages;per 3',per 5'

NFATC1 SRGAP1 IQSEC2

2.65e-051911434cebaf31d4f09f4ab273a819ad5cbff7d9a9b341
ToppCell10x5'v1-week_12-13-Myeloid_macrophage|week_12-13 / cell types per 3 fetal stages;per 3',per 5'

NFATC1 SRGAP1 IQSEC2

2.65e-05191143be2fe2583bdcee0b35c43a347da9c4adb93e30e0
ToppCellfacs-Skin-Anagen-24m-Epithelial-inner_bulge|Skin / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation

SLX4 CTIF

4.37e-0410014297ca9cda55a05fbb4d1f5d61f847c965e014f05c
ToppCellfrontal_cortex-Neuronal-glutamatergic_neuron-L5_IT-L5_IT_ALM_Npw|frontal_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype

OTOP2 RTN4RL1

5.58e-04113142165de4316059222f33d1e51aeff4554037c0b937
ToppCellrenal_cortex_nuclei-Hypertensive_with+without-CKD-Epithelial-Collecting_tubule_epithelial_cell-kidney_collecting_duct_intercalated_cell-Transitional_Principal-Intercalated_Cell|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group

CANT1 SLX4

8.54e-04140142e64f6aa57bc069cfe970089bd1c298433bfaf771
ToppCell10x5'-Lung-Myeloid_Mac-Intestinal_macrophages|Lung / Manually curated celltypes from each tissue

RTN4RL1 SRGAP1

8.66e-041411427671d300b1722711fd2d8034b96a3aa7e3ccb560
ToppCellFrontal_cortex-Neuronal-Excitatory-eN1(Slc17a7)-eN1_2-Nptxr|Frontal_cortex / BrainAtlas - Mouse McCarroll V32

OTOP2 RTN4RL1

9.53e-04148142223d6a640f3c34e73646a615593b9c0b4a4cbd6f
ToppCellfacs-Liver-Non-hepatocytes-3m-Lymphocytic-NK_cell|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation

RTN4RL1 SLX4

1.03e-0315414275eac6970259a6916fcfa6d3400509cfa2d98d9d
ToppCellnormal_Pleural_Fluid-T/NK_cells-CD4+_Th|T/NK_cells / Location, Cell class and cell subclass

RTN4RL1 IQSEC2

1.17e-03164142334f376350c9cf92611d0f75b2e18a102f4c116a
ToppCellDendritic_Cells-Donor_02|World / lung cells shred on cell class, cell subclass, sample id

SRGAP1 IRS2

1.20e-03166142fbeb74b98b58085de323f744b18d4a8f7b22d5d4
ToppCellrenal_medulla_nuclei-Adult_normal_reference-Mesenchymal-glomerular_mesenchymal_cell|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group

RTN4RL1 IRS2

1.21e-03167142b4ef07117d14da3d5fbced949e4dfcb01c392295
ToppCellrenal_medulla_nuclei-Adult_normal_reference-Mesenchymal-glomerular_mesenchymal_cell-Mesangial_Cell-mesangial_typical|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group

RTN4RL1 IRS2

1.21e-0316714294fc7df7ca55cd722a8dbd153201a29891217473
ToppCellrenal_medulla_nuclei-Adult_normal_reference-Mesenchymal-glomerular_mesenchymal_cell-Mesangial_Cell|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group

RTN4RL1 IRS2

1.21e-03167142eff3723fe60755272eca237459165e436e919ece
ToppCell368C-Lymphocytic-CD8+_Cytotoxic_T-cell-CD8+_Cytotoxic_T_cell_1.5|Lymphocytic / Donor, Lineage, Cell class and subclass (all cells)

MAST2 CTIF

1.22e-0316814294cded2e953c0970bf2f3dbe0ce46bd77a5ed8c7
ToppCelldroplet-Marrow-nan-24m-Lymphocytic-NK_cell|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation

NFATC3 SRGAP1

1.22e-03168142e979a4fbeb9f21048b47d69e6da75c57650697f2
ToppCellfacs-Lung-ENDOMUCIN-18m-Lymphocytic-Ly6g5b+_T|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation

NFATC3 SLX4

1.27e-031711421fb4e11f92b48dc2d6e553c22e2571bbd8c223c6
ToppCellfacs-Lung-ENDOMUCIN-18m-Lymphocytic-T_cell|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation

NFATC3 SLX4

1.27e-03171142246fc7edcefc47437d1df6029f295aca3b34b2b2
ToppCelldroplet-Marrow-nan-18m-Myeloid-basophil|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation

CTIF IQSEC2

1.31e-0317414255cc8300489d11322724159ec7d0e1d32a702e91
ToppCellrenal_cortex_nuclei-CKD+DKD_normotensive-Mesenchymal-Fibroblast-kidney_interstitial_fibroblast-kidney_interstitial_fibroblast_5|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group

NFATC1 SRGAP1

1.33e-03175142910a075ccaf79de22338ecf321fa0a867f3d7d75
ToppCellRSV-Healthy-1|Healthy / Virus stimulation, Condition and Cluster

NFATC3 SLX4

1.33e-03175142ff3a27f512a3a710ebc863b7b75cce8167d5440b
ToppCellRSV-Healthy-1|RSV / Virus stimulation, Condition and Cluster

NFATC3 SLX4

1.33e-03175142ca52b99b03535a5b3a2751d6981708dc5b255b91
ToppCellrenal_cortex_nuclei-CKD+DKD_normotensive-Mesenchymal-Fibroblast-kidney_interstitial_fibroblast|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group

NFATC1 SRGAP1

1.33e-03175142f0c2eb82e17e8aec2cfa5d83169178f409cc1abc
ToppCellE18.5-Epithelial-Epithelial_Alveolar-Epithelial_Alveolar-AT1-AT1_prolif|E18.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

SLX4 SRGAP1

1.33e-03175142711ace94fa9a763c6ae48171a690953f25deebe4
ToppCellrenal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Endothelial-lymphatic_endothelial_cell-lymphatic_endothelial_cell_of_renal_cortex-lymphatic_endothelial_cell_of_renal_cortex_prolif|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group

CANT1 SRGAP1

1.34e-031761428eb91dcf55d4e3e28a72d447181bf6d2ad891fc6
ToppCell10x5'v1-week_17-19-Myeloid_macrophage-stroma-erythroid_macrophage|week_17-19 / cell types per 3 fetal stages;per 3',per 5'

RTN4RL1 SRGAP1

1.36e-03177142b647667da62a91dbe3890820142626e26aa779d2
ToppCellRV-11._Adipocyte|RV / Chamber and Cluster_Paper

CTIF IRS2

1.37e-03178142278bbea5cf8f0589f71675c7a3d00679391b5253
ToppCelldroplet-Spleen-nan-24m-Myeloid-macrophage_dendritic_cell_progenitor|Spleen / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation

RTN4RL1 CTIF

1.39e-03179142d50d29f26d5a2cd8c4cd4e1244e1bb8de072d159
ToppCellRA-11._Adipocyte|RA / Chamber and Cluster_Paper

RTN4RL1 CTIF

1.40e-03180142d48a3d27357f7d184132a6805950f93080146b59
ToppCellCOPD-Myeloid-cMonocyte|World / Disease state, Lineage and Cell class

SRGAP1 IRS2

1.47e-03184142ceec41ed5636032aaf7716d1203816ea58bd39bd
ToppCellfacs-Limb_Muscle-ForelimbandHindlimb|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation

NFATC1 IRS2

1.48e-03185142eb7d3c1363d5fedc611f9c1a91ea823de251355e
ToppCelldroplet-Lung-nan-18m-Mesenchymal-pulmonary_interstitial_fibroblast|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation

RTN4RL1 SRGAP1

1.50e-03186142b58db5abdd3e9f0214b198c3cbd09b0b3c321eab
ToppCellSmart-seq2-blood_(Smart-seq2)-myeloid-myeloid_monocytic-classical_monocyte|blood_(Smart-seq2) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type

SRGAP1 IRS2

1.50e-0318614223b8d51d20b05795a73892d3e20e0f9b6a207820
ToppCell343B-Myeloid-Macrophage-M2-like_Macrophage_(MARCO_negative)|Myeloid / Donor, Lineage, Cell class and subclass (all cells)

RTN4RL1 SRGAP1

1.50e-031861429673367cb53bafb873a01ef6bda11d9f392ce648
ToppCelldroplet-Lung-nan-18m-Mesenchymal-Myofibroblast|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation

RTN4RL1 SRGAP1

1.50e-03186142cd6502bbf9dce318fdbb4965d49df8951e5f795c
ToppCelldroplet-Liver-LIVER_HEP-30m-Lymphocytic-nan|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation

RTN4RL1 IRS2

1.50e-03186142f5468e03321ea2083e223eb0d92c3a9307039569
ToppCellfacs-SCAT-Fat-3m-Lymphocytic-B_cell|SCAT / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation

NFATC3 IRS2

1.50e-03186142d5d990d8b6ccd8ca8fe7d0d7dedbe2359ae7b582
ToppCellPBMC_fresh-frozen-Severe-critical_progression_d12-22_with-steroid-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell-T_CD4_c06-NR4A2|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k)

NFATC1 IRS2

1.53e-03188142939790f133eac9c12d08db6ddb5f08f5107844e3
ToppCellRA-11._Adipocyte|World / Chamber and Cluster_Paper

RTN4RL1 CTIF

1.53e-031881424dac9d636e5cad4cda540b93d4bfed6b5732c880
ToppCellfacs-Brain_Myeloid-Striatum-3m-Myeloid-nan|Brain_Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation

RTN4RL1 TNKS2

1.55e-031891426dd4ec5ce4beb856f0d2d1654e3c4676d1d63736
ToppCellfacs-Brain_Myeloid-Striatum-3m-Myeloid-microglial_cell|Brain_Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation

RTN4RL1 TNKS2

1.55e-03189142875df61ee48baa5142ba4d2427bdec1c53e5a828
ToppCellPBMC_fresh-frozen-Severe-critical_progression_d12-22_with-steroid-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell-T_CD4_c07-AHNAK|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k)

NFATC1 IRS2

1.55e-03189142284f39dfacec76004daae9dd5317fb7b1f04fa99
ToppCellfacs-Brain_Myeloid-Striatum-3m-Myeloid|Brain_Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation

RTN4RL1 TNKS2

1.55e-031891423ae479ec7e00c57127cbe51a398329b10ca9848c
ToppCellfacs-Brain_Myeloid-Striatum-3m|Brain_Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation

RTN4RL1 TNKS2

1.55e-0318914297ef5215d841ff366a3e3682cd9bd04100cbfde0
ToppCellrenal_cortex_nuclei-CKD+DKD_normotensive-Mesenchymal-Fibroblast-Collagen-low_Matrisome-low_fibroblast|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group

NFATC1 SRGAP1

1.56e-03190142048b581e3f7ea9fc2f87c0532974bba85c7292c2
ToppCellMonocytes-Tissue-resident_macrophages|World / Immune cells in Kidney/Urine in Lupus Nephritis

SRGAP1 IRS2

1.56e-0319014207215e8f292cb54c670037aaf28393cddbe5548c
ToppCellrenal_cortex_nuclei-CKD+DKD_normotensive-Mesenchymal-Fibroblast-Collagen-low_Matrisome-low_fibroblast-|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group

NFATC1 SRGAP1

1.56e-031901421121eb607a984c59fbffe7220837fc178745aa55
ToppCellfacs-Lung-3m-Mesenchymal-myofibroblast|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype

RTN4RL1 IRS2

1.58e-03191142fd8331c7abdd999f55ba43d307945c6abfccbf84
ToppCellrenal_cortex_nuclei-CKD+DKD_normotensive|renal_cortex_nuclei / Celltypes from Cells and Nuclei per compartment and clinical group

NFATC1 SRGAP1

1.59e-031921428b86db2ebe0199fee0e9800566a619a24bfdeed5
ToppCellMonocytes-Tissue-resident_macrophages|Monocytes / Immune cells in Kidney/Urine in Lupus Nephritis

SRGAP1 IRS2

1.61e-03193142198552810dcac8d0ca63a78badd6702b49ff6edf
ToppCellChildren_(3_yrs)-Mesenchymal-matrix_fibroblast_1_cell-D139|Children_(3_yrs) / Lineage, Cell type, age group and donor

SRGAP1 IRS2

1.63e-03194142e93de9428c986b8943fc169258847c650cfab0e5
ToppCell10x3'2.3-week_14-16-Myeloid_macrophage-stroma|week_14-16 / cell types per 3 fetal stages;per 3',per 5'

NFATC1 SRGAP1

1.66e-03196142bd2c2de103e28b65ea537c22f71225cb0deef1e0
ToppCell10x3'2.3-week_14-16-Myeloid_macrophage|week_14-16 / cell types per 3 fetal stages;per 3',per 5'

NFATC1 SRGAP1

1.66e-03196142072a4150ae521c6589b0f7cd60e975fb33715bf4
ToppCellrenal_cortex_nuclei-CKD+DKD_normotensive-Mesenchymal-Fibroblast-Collagen+matrisome-high_fibroblast-|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group

NFATC1 SRGAP1

1.68e-0319714285a8f1d18e0dd1d31341f5131eecd217553bf042
ToppCellrenal_cortex_nuclei-CKD+DKD_normotensive-Mesenchymal-Fibroblast-Collagen+matrisome-high_fibroblast|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group

NFATC1 SRGAP1

1.68e-03197142e8e3ba791dfaa0fab35e0329a5e34376f9ee6143
ToppCell10x3'2.3-week_12-13-Myeloid_macrophage-stroma-osteoclast|week_12-13 / cell types per 3 fetal stages;per 3',per 5'

NFATC1 SRGAP1

1.68e-031971421bf69db7e830315c8fa85e6e85b0cb94014e9169
ToppCellrenal_cortex_nuclei-CKD+DKD_normotensive-Mesenchymal|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group

NFATC1 SRGAP1

1.68e-031971429b480f9c799a244bfee64487abd8a1bf07c9a3a2
ToppCellB_cells-Naive_B_cells_|B_cells / Immune cells in Rheumatoid Arthritis Joint Synovial Tissues

NFATC1 IRS2

1.68e-03197142fd5fdc5289d681d59ff22d72e4de6e74c6c7aac6
ToppCellmLN-T_cell-Activated_CD4_T|T_cell / Region, Cell class and subclass

NFATC1 IRS2

1.69e-03198142404ec46bd39b6f4d02a03ef38c30850bbbd8b608
ToppCellrenal_cortex_nuclei-CKD+DKD_normotensive-Mesenchymal-Fibroblast|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group

NFATC1 SRGAP1

1.69e-03198142a860246bcea847249a78fd2e86ed8e04371060db
ToppCellParenchyma_COVID-19-Immune-TX-MoAM-4|Parenchyma_COVID-19 / Sample group, Lineage and Cell type

NFATC1 SRGAP1

1.69e-03198142a7eed9eeb728a8796e2780090cc244856efd8c65
ToppCellBronchial-NucSeq-Immune_Myeloid-Macrophage_alveolar-Macro_alv_MT|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations

NFATC1 SRGAP1

1.71e-03199142951c2ea5af4756832c2adcec3ee70a7e36331a4e
ToppCellTransverse-T_cell-Tfh|T_cell / Region, Cell class and subclass

SRGAP1 TNKS2

1.71e-0319914233ffea12b8228e0b5bd8942531c3b21d24224725
ToppCellTransverse-(1)_T_cell-(16)_Tfh|Transverse / shred on region, Cell_type, and subtype

SRGAP1 TNKS2

1.71e-03199142aa31e26d48066f865ca33251a33a28934c0a7a44
ToppCellTransverse-T_cell-Tfh|Transverse / Region, Cell class and subclass

SRGAP1 TNKS2

1.71e-03199142cbef8f95edf2e86e16c448a76068d7ed8f6b7748
ToppCellBronchial-NucSeq-Epithelial-Epi_submucosal-gland|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations

SRGAP1 IRS2

1.73e-0320014285c0f038bcfb42669dca2b80273b0f8a1421405e
ToppCellBronchial-NucSeq-Epithelial-Epi_submucosal-gland-SMG_Mucous|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations

SRGAP1 IRS2

1.73e-03200142ed093626a9cac7531a2bf02f6e345c5e84b8c060
ComputationalGenes in the cancer module 262.

NFATC1 IRS2

5.08e-0410042MODULE_261
DrugNSC92228

NFATC1 NFATC3

1.05e-063142CID000017897
DrugCephalexin monohydrate [23325-78-2]; Up 200; 11uM; MCF7; HT_HG-U133A

NFATC3 IRS2 IQSEC2 TNKS2

4.98e-061961442628_UP
Drug(-)-Cinchonidine [485-71-2]; Up 200; 13.6uM; HL60; HG-U133A

MAST2 SNIP1 CTIF IRS2

5.29e-061991441780_UP
DrugINCA-6

NFATC1 NFATC3

2.31e-0512142CID000230748
Drugtyrosinate

NFATC1 NFATC3 IRS2

9.30e-05148143CID000001153
Drugh EIT

NFATC1 NFATC3

1.04e-0425142CID000452078
DrugLY 294002; Up 200; 10uM; PC3; HT_HG-U133A

NFATC3 IRS2 IQSEC2

1.69e-041811431236_UP
DrugLY 294002; Up 200; 10uM; MCF7; HT_HG-U133A

NFATC3 IRS2 IQSEC2

1.71e-041821431661_UP
DrugMethylprednisolone, 6-alpha [83-43-2]; Up 200; 10.6uM; HL60; HG-U133A

MAST2 CTIF IRS2

1.80e-041851431567_UP
DrugTolbutamide [64-77-7]; Down 200; 14.8uM; MCF7; HT_HG-U133A

MAST2 NFATC3 IRS2

1.95e-041901434362_DN
Drugtrichostatin A; Up 200; 0.1uM; PC3; HG-U133A

MAST2 CTIF IRS2

1.98e-04191143448_UP
DrugMetixene hydrochloride [1553-34-0]; Up 200; 11.6uM; MCF7; HT_HG-U133A

NFATC3 CTIF IRS2

2.01e-041921433313_UP
Drugradicicol, diheterospora chlamydosporia; Up 200; 0.1uM; MCF7; HT_HG-U133A

CTIF IRS2 IQSEC2

2.04e-041931436938_UP
DrugSulfacetamide sodic hydrate [6209-17-2]; Up 200; 15.8uM; PC3; HT_HG-U133A

IRS2 IQSEC2 TNKS2

2.04e-041931431817_UP
DrugTolazamide [1156-19-0]; Up 200; 12.8uM; MCF7; HT_HG-U133A

IRS2 IQSEC2 TNKS2

2.04e-041931432842_UP
DrugAlverine citrate salt [5560-59-8]; Down 200; 8.4uM; PC3; HT_HG-U133A

NFATC1 NFATC3 TNKS2

2.04e-041931436345_DN
DrugMetergoline [17692-51-2]; Up 200; 10uM; HL60; HG-U133A

CANT1 NFATC3 IQSEC2

2.07e-041941431606_UP
DrugTiletamine hydrochloride; Down 200; 15.4uM; MCF7; HT_HG-U133A

MAST2 IRS2 TNKS2

2.07e-041941436516_DN
Drughaloperidol; Down 200; 10uM; HL60; HT_HG-U133A

MAST2 NFATC1 NFATC3

2.10e-041951436163_DN
DrugEthamsylate [2624-44-4]; Down 200; 15.2uM; MCF7; HT_HG-U133A

IRS2 IQSEC2 TNKS2

2.10e-041951434399_DN
DrugSpironolactone [52-01-7]; Up 200; 9.6uM; PC3; HT_HG-U133A

MAST2 SNIP1 TNKS2

2.10e-041951432064_UP
DrugAlfaxalone [23930-19-0]; Down 200; 12uM; HL60; HT_HG-U133A

MAST2 NFATC3 CTIF

2.10e-041951433135_DN
Drug6-Furfurylaminopurine [525-79-1]; Down 200; 18.6uM; HL60; HT_HG-U133A

MAST2 NFATC3 SNIP1

2.13e-041961432511_DN
DrugFluorometholone [426-13-1]; Down 200; 10.6uM; MCF7; HT_HG-U133A

MAST2 CANT1 TNKS2

2.13e-041961436247_DN
DrugTimolol maleate salt [26921-17-5]; Down 200; 9.2uM; MCF7; HT_HG-U133A

MAST2 IQSEC2 TNKS2

2.13e-041961436483_DN
Drugprochlorperazine dimaleate salt; Down 200; 10uM; PC3; HT_HG-U133A

MAST2 NFATC1 IQSEC2

2.13e-041961434439_DN
DrugCyproheptadine hydrochloride [969-33-5]; Up 200; 12.4uM; PC3; HT_HG-U133A

NFATC1 CTIF IQSEC2

2.13e-041961436740_UP
DrugDicloxacillin sodium salt [13412-64-1]; Up 200; 8.2uM; MCF7; HT_HG-U133A

NFATC3 CTIF IRS2

2.16e-041971433307_UP
DrugGlipizide [29094-61-9]; Down 200; 9uM; MCF7; HT_HG-U133A

MAST2 IRS2 IQSEC2

2.16e-041971431508_DN
DrugAcetaminophen [103-90-2]; Down 200; 26.4uM; MCF7; HT_HG-U133A

MAST2 IRS2 IQSEC2

2.16e-041971433364_DN
Drug(+) -Levobunolol hydrochloride [47141-41-3]; Down 200; 12.2uM; MCF7; HT_HG-U133A

MAST2 NFATC3 IQSEC2

2.16e-041971433355_DN
DrugChlormezanone [80-77-3]; Down 200; 14.6uM; MCF7; HT_HG-U133A

MAST2 NFATC3 IQSEC2

2.16e-041971433235_DN
DrugFlutamide [13311-84-7]; Down 200; 14.4uM; MCF7; HT_HG-U133A

CTIF IRS2 IQSEC2

2.16e-041971433885_DN
DrugFamotidine [76824-35-6]; Up 200; 11.8uM; MCF7; HT_HG-U133A

NFATC3 IRS2 TNKS2

2.20e-041981431529_UP
DrugLevocabastine hydrochloride [79547-78-7]; Up 200; 8.8uM; MCF7; HT_HG-U133A

NFATC3 CTIF TNKS2

2.20e-041981433509_UP
DrugMeclofenoxate hydrochloride [3685-84-5]; Down 200; 13.6uM; MCF7; HT_HG-U133A

MAST2 NFATC3 TNKS2

2.20e-041981434729_DN
DrugDanazol [17230-88-5]; Up 200; 11.8uM; MCF7; HT_HG-U133A

CTIF IRS2 TNKS2

2.20e-041981431538_UP
Drug(S)-(-)-Atenolol [93379-54-5]; Down 200; 15uM; MCF7; HT_HG-U133A

MAST2 NFATC3 SNIP1

2.20e-041981436444_DN
DrugTetracycline hydrochloride [64-75-5]; Down 200; 8.4uM; MCF7; HT_HG-U133A

MAST2 CTIF IQSEC2

2.23e-041991432243_DN
Drug(-) -Levobunolol hydrochloride [27912-14-7]; Down 200; 12.2uM; PC3; HT_HG-U133A

MAST2 CTIF IQSEC2

2.23e-041991434016_DN
DrugCalycanthine [595-05-1]; Up 200; 11.6uM; HL60; HG-U133A

MAST2 CTIF IRS2

2.23e-041991431771_UP
DrugTropicamide [1508-75-4]; Down 200; 14uM; HL60; HT_HG-U133A

CANT1 NFATC3 SNIP1

2.23e-041991432347_DN
DrugXylometazoline hydrochloride [1218-35-5]; Down 200; 14.2uM; MCF7; HT_HG-U133A

MAST2 NFATC3 SNIP1

2.23e-041991437020_DN
DrugTrimethylcolchicinic acid [3482-37-9]; Down 200; 11.6uM; MCF7; HT_HG-U133A

MAST2 NFATC3 TNKS2

2.23e-041991432802_DN
DrugNitrofurantoin [67-20-9]; Up 200; 16.8uM; HL60; HT_HG-U133A

MAST2 NFATC1 IQSEC2

2.23e-041991432341_UP
DrugWY-14643; Up 200; 100uM; PC3; HG-U133A

MAST2 NFATC1 NFATC3

2.26e-04200143481_UP
DrugSaquinavir mesylate [149845-06-7]; Down 200; 5.2uM; HL60; HT_HG-U133A

MAST2 NFATC1 IQSEC2

2.26e-042001436127_DN
DrugKhellin [82-02-0]; Up 200; 15.4uM; MCF7; HT_HG-U133A

NFATC3 IRS2 IQSEC2

2.26e-042001431504_UP
Drugsaran

NFATC1 NFATC3

2.44e-0438142CID000062706
DrugHarmine

NFATC1 NFATC3

3.13e-0443142ctd:D006247
Drug7-amino-AMD

NFATC1 NFATC3

5.69e-0458142CID000065180
DrugNSC302991

CANT1 IRS2 TNKS2

1.18e-03353143CID000002538
Drugmetolachlor

NFATC1 NFATC3

1.30e-0388142CID000004169
DrugCalcimycin

NFATC1 NFATC3

2.90e-03132142ctd:D000001
DrugLanatoside C [17575-22-3]; Up 200; 4uM; PC3; HT_HG-U133A

SNIP1 IRS2

4.17e-031591424328_UP
DrugDigoxigenin [1672-46-4]; Up 200; 10.2uM; MCF7; HT_HG-U133A

SNIP1 IRS2

4.23e-031601425275_UP
DrugPyrvinium pamoate [3546-41-6]; Up 200; 3.4uM; MCF7; HT_HG-U133A

CTIF IRS2

4.28e-031611425439_UP
DrugLanatoside C [17575-22-3]; Up 200; 4uM; MCF7; HT_HG-U133A

SNIP1 IRS2

4.43e-031641423963_UP
DrugDigitoxigenin [143-62-4]; Up 200; 10.6uM; MCF7; HT_HG-U133A

SNIP1 IRS2

4.49e-031651423275_UP
DrugDigoxigenin [1672-46-4]; Up 200; 10.2uM; MCF7; HT_HG-U133A

SNIP1 IRS2

4.59e-031671425640_UP
DrugStrophanthidin [66-28-4]; Up 200; 9.8uM; MCF7; HT_HG-U133A

SNIP1 IRS2

4.65e-031681426087_UP
Druggeldanamycin; Up 200; 1uM; MCF7; HT_HG-U133A

IRS2 TNKS2

4.70e-031691425225_UP
Drugthioridazine hydrochloride; Up 200; 10uM; MCF7; HT_HG-U133A

NFATC3 IRS2

4.86e-031721426989_UP
DrugParthenolide [20554-84-1]; Up 200; 16.2uM; PC3; HT_HG-U133A

CTIF IRS2

4.92e-031731425105_UP
DrugThonzonium bromide [553-08-2]; Up 200; 6.8uM; PC3; HT_HG-U133A

CTIF IRS2

4.92e-031731424617_UP
DrugTrichostatin A, from Streptomyces sp.; Up 200; 0.1uM; PC3; HT_HG-U133A

IRS2 IQSEC2

4.92e-031731422105_UP
DrugIsoflupredone acetate [338-98-7]; Up 200; 9.6uM; HL60; HT_HG-U133A

MAST2 IRS2

4.97e-031741421873_UP
DrugTrichostatin A, from Streptomyces sp.; Up 200; 0.1uM; PC3; HT_HG-U133A

IRS2 IQSEC2

4.97e-031741427136_UP
Drug0179445-0000 [211246-22-9]; Up 200; 10uM; MCF7; HT_HG-U133A

NFATC3 CTIF

5.26e-031791423630_UP
DrugStrophantine octahydrate [11018-89-6]; Up 200; 5.4uM; MCF7; HT_HG-U133A

IRS2 IQSEC2

5.26e-031791422656_UP
DrugPuromycin dihydrochloride [58-58-2]; Down 200; 7.4uM; MCF7; HT_HG-U133A

MAST2 CANT1

5.31e-031801425310_DN
DrugCycloheximide [66-81-9]; Down 200; 14.2uM; MCF7; HT_HG-U133A

MAST2 CANT1

5.37e-031811426220_DN
DrugSecurinine [5610-40-2]; Up 200; 18.4uM; PC3; HT_HG-U133A

NFATC3 CTIF

5.37e-031811424493_UP
DrugAstemizole [68844-77-9]; Up 200; 8.8uM; PC3; HT_HG-U133A

IRS2 IQSEC2

5.43e-031821422049_UP
Drug17-DMAG; Up 200; 0.1uM; HL60; HT_HG-U133A

NFATC1 IQSEC2

5.49e-031831421154_UP
Drug17-AAG; Up 200; 1uM; MCF7; HT_HG-U133A

NFATC3 IQSEC2

5.49e-031831426937_UP
DrugRimexolone [49697-38-3]; Down 200; 10.8uM; HL60; HT_HG-U133A

CANT1 NFATC3

5.55e-031841422955_DN
DrugICI182,780; Down 200; 1uM; MCF7; HT_HG-U133A

CTIF IRS2

5.55e-031841427490_DN
DrugPerphenazine [58-39-9]; Up 200; 10uM; MCF7; HT_HG-U133A

NFATC3 IRS2

5.55e-031841421540_UP
DrugLY 294002; Up 200; 10uM; MCF7; HT_HG-U133A_EA

MAST2 IRS2

5.55e-031841421007_UP
DrugRapamycin; Up 200; 0.1uM; PC3; HT_HG-U133A

CTIF TNKS2

5.60e-031851424445_UP
DrugHelveticoside [630-64-8]; Down 200; 7.4uM; MCF7; HT_HG-U133A

NFATC1 CANT1

5.66e-031861423851_DN
DrugLY 294002; Up 200; 10uM; MCF7; HT_HG-U133A

NFATC3 IRS2

5.66e-031861426987_UP
DrugMetoclopramide monohydrochloride [7232-21-5]; Down 200; 11.8uM; HL60; HT_HG-U133A

NFATC3 SNIP1

5.66e-031861422353_DN
Diseasefasting blood glucose measurement

NFATC1 NFATC3 RTN4RL1

3.06e-04287143EFO_0004465
Diseaseeye colour measurement

RTN4RL1 CTIF

4.66e-03218142EFO_0009764
Diseaseheart rate

NFATC1 CTIF

4.96e-03225142EFO_0004326
Diseasered blood cell density measurement

MAST2 CTIF IRS2

7.52e-03880143EFO_0007978
Diseasemyeloid white cell count

MAST2 CTIF TNKS2

8.94e-03937143EFO_0007988
Diseasehematocrit

MAST2 CTIF IRS2

1.10e-021011143EFO_0004348
Diseasealkaline phosphatase measurement

NFATC1 NFATC3 TNKS2

1.11e-021015143EFO_0004533
Diseasereticulocyte count

MAST2 CTIF IRS2

1.20e-021045143EFO_0007986
Diseasewhite matter microstructure measurement

MAST2 NFATC1

1.43e-02390142EFO_0005674
Diseasefatty acid measurement

RTN4RL1 CTIF

1.76e-02436142EFO_0005110
DiseaseCrohn's disease

NFATC1 CTIF

1.80e-02441142EFO_0000384
Diseaseinflammatory bowel disease

NFATC1 CTIF

1.86e-02449142EFO_0003767
Diseaseblood urea nitrogen measurement

NFATC1 NFATC3

1.89e-02452142EFO_0004741
Diseaserheumatoid arthritis

NFATC1 CTIF

1.97e-02462142EFO_0000685
Diseasetestosterone measurement

NFATC1 IQSEC2 TNKS2

2.05e-021275143EFO_0004908

Protein segments in the cluster

PeptideGeneStartEntry
SAPHPSGRPTHHGYS

CTIF

231

O43310
SPHGPTRSKGHPHGP

RTN4RL1

331

Q86UN2
PGSRPPGGSYSHPHH

IQSEC2

1406

Q5JU85
SHRPAPGRPPTHNAH

CANT1

61

Q8WVQ1
PYSPHHSPTPSPHGS

NFATC1

276

O95644
SPREHPLSPHHASGG

NUTM1

1031

Q86Y26
HRGPPGAEPHSTHPK

OTOP2

426

Q7RTS6
HPLHHGPGQRPSSGS

IRS2

471

Q9Y4H2
LPRPHSPLHGHTGNS

MAST2

186

Q6P0Q8
PAHRRPDHSGGSPSP

SNIP1

41

Q8TAD8
PGRTSDGHCPLHPPH

SRGAP1

861

Q7Z6B7
RSPSRPHPGGHPHSS

SLX4

1341

Q8IY92
SLSPHHSPVPSPGHS

NFATC3

286

Q12968
AHSPPGHHSVTGRPS

TNKS2

1116

Q9H2K2
TSPSPPGAHHPLGTH

nan

101

Q6ZRN7